WAPN+ facilitated a treatment literacy and advocacy training forum in Bangkok, Thailand, at the end of September 2010. The training was attended by 22 participants from 13 countries in the Asia Pacific region.

  Treatment literacy can be defined as understanding HIV/AIDS and all aspects of antiretroviral therapy (ART), including types of ARV drugs, how they work, ARV side effects, treatment adherence, HIV drug resistance and other issues. Treatment literacy is essential to ensuring that people living with HIV are well informed and in a position to participate more actively in treatment, including communicating treatment needs to health care providers.  It is also important to have the knowledge and capacity to hold governments accountable and to ensure they improve the quality and accessibility of health services and the quality of ARV treatment.

The attached report provides a full account of the 3 day forum.

Organization: APN+

Weblink: http://www.apnplus.org/main/Index.php?module=news&news=64



详细信息请参考为期三天的培训报告:Report WAPN TL Training 30 Sep-2 Oct 2010_New.pdf

机构: APN+ - 亚太艾滋病感染者网络



On June 5, 1981, an article concerning five previously healthy, young gay men in Los Angeles diagnosed with Pneumocystis carinii pneumonia, an infection that usually appears only in individuals with substantial immune system damage, appeared in the Morbidity and Mortality Weekly Report, a publication of the Centers for Disease Control and Prevention.
Soon more cases like these appeared, at first mainly in gay men, but then also in injection drug users, hemophiliacs and other recipients of blood and blood products, heterosexual men and women, and babies who acquired the infection from their mothers during birth or breastfeeding. We and our colleagues quickly began to confront the reality of a deadly new disease that would change the world. The disease ultimately would be referred to as AIDS.

Thirty years later, we are gratified by the progress that has been made in understanding, treating and preventing HIV/AIDS. We could not have imagined these advances during the early days of AIDS, when all we could do was provide palliative care to waves of dying patients. Whereas survival was once measured in weeks or months from the time of diagnosis, today, the critical discovery of antiretroviral drugs and their use in combination regimens has resulted in greatly improved life expectancy -- decades, rather than months -- for many HIV-infected people who have access to these medicines and adhere to treatment.

We take pride in the contributions of NIH-supported scientists who have been central to the investigation of the HIV disease process, the development of new therapies for HIV/AIDS and the design and validation of methods of HIV prevention. NIH scientists played a key role in demonstrating that HIV causes AIDS and in developing a diagnostic test for the virus. The ability to test the blood supply for HIV has nearly eliminated the risk of HIV transmission through blood transfusion.

NIH has supported basic and clinical research that provided pivotal data for many of the more than 30 drugs that have been approved by the Food and Drug Administration to treat HIV infection, as well as for strategies to address its associated opportunistic infections, malignancies and clinical complications. Clinical trials funded by NIH also have helped determine the most effective combinations of these drugs to slow or halt the progression of HIV disease. Additionally, NIH-supported studies were instrumental in designing effective strategies to virtually eliminate mother-to-child HIV transmission in developed nations and to dramatically reduce HIV transmission from an infected mother to her newborn or nursing child in the developing world. Many of these clinical trials were designed with the involvement and advice of HIV-affected communities, establishing a model for the conduct of clinical trials for other diseases.

NIH-supported, large-scale clinical trials have resulted in other notable achievements in HIV prevention. These studies sought answers to questions of critical importance to the global public health community. They proved that medically supervised adult male circumcision <http://www.niaid.nih.gov/news/newsreleases/2006/Pages/AMC12_06.aspx> more than halves the risk of female-to-male sexual HIV transmission; that needle and syringe exchange programs can reduce HIV transmission without increasing injection drug use; that a vaccine <http://www.niaid.nih.gov/news/newsreleases/2009/pages/thaivaxstudy.aspx> can achieve modest protection against HIV infection; and that taking an antiretroviral drug daily <http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx> can reduce the risk of HIV acquisition in men who have sex with men.

Most recently, an NIH-funded clinical trial <http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx> demonstrated that an HIV-infected individual can dramatically reduce the risk of transmitting the virus to an uninfected heterosexual partner by starting treatment when his or her immune system is relatively healthy. NIH also helped train the scientists and establish the infrastructure for an important clinical trial funded by the U.S. Agency for International Development showing that a vaginal gel containing an anti-HIV drug can help protect women from HIV infection. These multiple achievements are important because it is clear that controlling -- and ultimately ending -- the HIV/AIDS pandemic will require a combination of scientifically proven HIV prevention tools.

As gratified as we are by these accomplishments, we are sobered by some grim realities and remaining challenges. Despite the global public health community's best efforts to prevent new infections, 2.6 million people around the world became newly infected with HIV in 2009 alone. In developing nations, only about one-third of the 15 million people who need anti-HIV drugs have access to them. In addition, a growing proportion of patients receiving long-term antiretroviral therapy are experiencing treatment failure, drug toxicities, side effects and drug resistance. In this regard, recent studies have noted an increased incidence of malignancies, cardiovascular and metabolic complications and premature aging associated with long-term HIV disease or antiretroviral therapy.

NIH research will continue to address these issues as well as the causes of HIV-related health disparities, their role in disease transmission and acquisition, and their impact on treatment access and effectiveness. These include disparities among racial and ethnic populations in the United States; disparities between developed and resource-constrained nations, and disparities based on gender, age, or sexual identity. NIH research also will continue to play a critical role in providing the scientific foundation to achieve the goals of the President's National HIV/AIDS Strategy. Among the important scientific challenges that remain are the development of a safe and effective vaccine that can take its place among the combination of prevention tools as well as the possibility of curing at least a proportion of HIV-infected individuals.

The HIV/AIDS pandemic will remain one of the most serious public health crises of our time until better, more effective and affordable prevention and treatment regimens are developed and universally available. As the single largest public funder of HIV/AIDS research in the world, NIH is committed to advancing a comprehensive program of basic, clinical, translational and behavioral and social science research toward controlling and ultimately ending this modern plague. In memory of the patients, friends, loved ones and colleagues we have lost over these three decades, we wholeheartedly embrace this responsibility and opportunity knowing that history will judge us as much for what we accomplish during the coming years as for what we have achieved thus far.

Dr. Anthony S. Fauci is the director of the National Institute of Allergy and Infectious diseases. Dr. Jack Whitescarver is the NIH associate director for AIDS research and the director of the NIH Office of AIDS Research.

NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at <http://www.niaid.nih.gov/ >.

The Office of AIDS Research, a part of the Office of the NIH Director, coordinates the scientific, budgetary, legislative, and policy elements of the NIH AIDS research program.   OAR sets scientific priorities, enhances collaboration, and ensures that research dollars are invested in the highest priority areas of scientific opportunity that will lead to new tools in the global fight against AIDS.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
美国国家卫生研究院(NIH)医学博士Anthony S. Fauci、博士Jack Whitescarver为艾滋三十周年发表讲话。



    NIH支持的艾滋病预防大型临床实验取得了显著的成果。这些研究解答了很多全球卫生系统共同面临的问题,证明了在严格的医学监控下,对成年男性进行包皮环切手术能够降低一半以上由女性传染的艾滋病毒的风险(http://www.niaid.nih.gov/news/newsreleases/2006/Pages/AMC12_06.aspx );针头和注射器交换项目可以在不增加注射吸毒的基础上降低艾滋病毒的传播; 注射疫苗能在一定程度上防治艾滋感染(http://www.niaid.nih.gov/news/newsreleases/2009/pages/thaivaxstudy.aspx );每日服用抗逆转录药物能够降低男男性行为者感染艾滋的风(http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx )。

    最近,NIH支持的临床研究(http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx )表明,艾滋病毒感染者如果在自身免疫系统相对较健康的情况下开始治疗,其感染健康的异性性伴侣的可能性将大大降低。另外,NIH也协助美国国际开发署对其资助的临床研究人员进行培训,并提供研究所需的基础设施,该研究结果表明含有抗艾滋药物的阴道凝胶能够防治妇女感染艾滋。



    Anthony S. Fauci博士是NIH过敏症与传染病学部主管。Jack Whitescarver博士NIH艾滋研究部副主任以及NIH艾滋研究办主任。




| 评论(0)


A Toolkit for MSM-Led HIV and AIDS Advocacy

Speaking Out is an advocacy toolkit created to address the urgent need for men who have sex with men (MSM) everywhere to engage in advocacy locally, nationally, and globally to end the HIV epidemic and promote their human rights. The toolkit equips individuals and organizations with tools and techniques that enable them to become advocates right now, whoever and wherever they happen to be.

Now, more than ever, it is important for our communities to identify our own strengths, weaknesses, and needs, advocating as individuals and collectives for our rights in ways that work for us. MSM communities live and breathe in diverse and complex ways, and we must raise our voices on our own terms, from our respective contexts. That is what this toolkit is all about: ensuring we have the tools we need to become more involved in advocating for our rights, in our homes and schools as well as in governments and international forums.

This toolkit builds on advances made in past toolkits from around the world, with some key differences: (1) it is specifically MSM-focused with exercises and ideas that serve as conduits for the energy and contributions of MSM communities; (2) it is built on the belief that organizations can start where they are, and assumes that the skill sets of individual advocates and organizational maturity of MSM groups are wide-ranging and take time to develop; and (3) it approaches HIV and AIDS from a broad human rights framework, balancing public health and human rights approaches toward addressing MSM community susceptibility to HIV.

We hope you find this toolkit useful!  Please do not hesitate to write to us with any questions or concerns at speakingout@msmgf.org.


PDF Download>>

Weblink: http://www.msmgf.org/index.cfm/id/262









Asia Report 翻译

原文链接: http://www.msmgf.org/index.cfm/id/262






  Globally, women constitute approximately fifty percent of all HIV infections. Women may eventually comprise the majority of people living with HIV/AIDS in the world; this is already true in Sub-Saharan Africa where women constitute sixty percent of the individuals living with HIV. The recognition that women's inequality may be a driver of women's vulner- ability to contracting HIV has led to a series of feminist legal responses in an effort to address HIV.


  This Article assesses feminists' conflicting legal, policy, and regulatory proposals to address sex workers' vulnerability to contracting HIV. This Article employs a Governance Feminism ("GF") analysis that allows us to assess feminists as powerful actors in the institutions that govern HIV. This Article focuses on two cases in which particular legal and policy proposals can be traced directly to feminist engagement and disagreement: the drafting of the United Nations Joint Programme on HIV/AIDS Guidance Note on Sex Work and the creation and implementation of the Anti-Prostitution Loyalty Oath.

Download PDF>>


作者:Aziza Ahmed




  本文分析了不同的女性主义者针对性工作者感染艾滋的脆弱性所提出的相互冲突的法律、政策和管理方面的提案。文章采用Governance Feminism分析法让读者了解女权主义者作为有影响力的行动者,积极参与对艾滋问题的管理。本文关注的两个案例可以清晰地表明女权主义者如何参与不同的法律和政策提案,以及如何表达不一致的意见。这两个案例分别是:《联合国联合项目:艾滋指南与性工作须知》和《打击卖淫效忠誓言》的制定和实施。


   Booklet explains unique health needs and sets forth principles of practice for doctors, nurses and other healthcare providers.


  May 17, 2011 - The Global Forum on MSM & HIV (MSMGF) has published a new primer for doctors, nurses and other healthcare providers designed to improve the quality of clinical care available to men who have sex with men (MSM) across a broad range of contexts.  Released on May 17, the International Day against Homophobia, the booklet identifies stigma and discrimination as key barriers preventing MSM from accessing vital health services.


  Entitled "Engaging with Men Who Have Sex with Men in the Clinical Setting," the primer was developed in response to the unacceptable quality of care offered to MSM at clinics around the world.  High levels of homophobia among clinic staff have led to negligent care and severe violations of patient rights, such as verbal abuse and confidentiality breeches.  In addition, clinical curricula in many low- and middle-income countries have failed to include content on MSM health, leaving healthcare professionals with no knowledge of MSM health needs or the ways to address them.  


  Such substandard care has been a primary factor in the surge of HIV among MSM around the world as well as lower health outcomes overall.  More than half of MSM globally report that it is difficult or impossible to access vital services like HIV testing and treatment, while HIV prevalence rates skyrocket above 20% in countries like Senegal, Jamaica and Thailand.  Studies indicate that MSM also experience higher rates of depression, anxiety, substance abuse and suicide due to high levels of stress and alienation from social services and support.


  The primer aims to improve the standard of clinical care for MSM by providing basic knowledge about homosexuality and MSM health needs, as well as offering a set of principles for effective engagement of MSM in a healthcare setting.  The booklet begins by dispelling common myths about homosexuality and exploring the role of service providers in meeting the needs of MSM.  These needs are then examined in greater detail, with a focus on sexual health, mental health, drug use and violence.  The primer concludes with a roadmap for healthcare providers, providing guidance on leading community-level engagement with MSM and enhancing local capacity to meet MSM needs.


 "Healthcare providers play a central part in the well-being of MSM around the world," said Dr. George Ayala, Executive Officer of the MSMGF. "We have seen how damaging it can be when they are ill-equipped to handle the needs of MSM.  But with the proper tools at their disposal, they have the potential to be an equally powerful force for good.  This primer represents a first step toward that goal."


  The primer is currently available in English and can be found on the MSMGF's website at the following link:



  Translations are forthcoming in Russian, French and Spanish.  Any questions can be directed to contact@msmgf.org.

Organization: MSMGF



"男男性行为者所面临的医疗环境"为标题,该指南针对全球MSM群体所接受的质量低下的医护服务给予回应。由于医护人员对同性恋存在高度的恐惧,导致病 患的权利遭到忽视和践踏,例如言语攻击和个人信息外泄。另外,在很多中低收入国家,医疗课程并没有包含MSM健康的相关内容,因此医疗从业人员无法了解 MSM群体的健康需求,更不用谈如何满足这些需求。

由于目前艾滋病在MSM群体中迅速传播的现实,对此类医疗标准的需求更加凸显。全球超过一半的MSM人口表示很难或根本不可能获得艾滋病毒测试和治疗,而 与此同时,泰国、牙买家和塞内加尔的艾滋流行率迅速上升20% 研究显示由于无法获得社会服务与支持,MSM人口承受了极高的压力,导致该群体高频率的抑郁、焦虑、滥用药物和自杀。

本指南以提高MSM群体医护标准为目标,为医护人员提供同性恋和MSM健康需求的基本知识,同时也提供一整套行之有效的MSM医疗环境参与准则。针对 MSM健康需求,有以下几个主要分类:性健康、心理健康、药物使用与暴力。本指南为医护人员提供如何参与社区层面的MSM治疗,以及如何提高本土医疗能力 以满足MSM群体的需求。

Asia Report 翻译




加入邮件组: yzdc@asiacatalyst.org